Optima Chemical appoints Terry Rathman as consultant
A leading authority on lithium chemistry
Rathman has a reputation as ‘Mr Lithium’, emphasising his industry status as the foremost authority on lithium chemistry, according to Gene Williams, president of Optima Chemical.
‘He is the ideal addition to our organisation, which now offers lithium products such as alkyllithiums, aryllithiums, lithium amides and lithium alkoxides, resulting from our recent acquisition and licensing of selected products from FMC Lithium,’ he said.
‘I am eager to collaborate with my new colleagues, looking forward to assisting them in promoting lithium products that include and highlight those targeted to sophisticated pharmaceutical applications,’ added Rathman.
Rathman is sole proprietor of t-Links Consulting, based in Gastonia, North Carolina. Since 2002, Rathman has been a technical consultant to Calvert Holdings, Chiral Technologies, PetroCrystals and Honeywell Pharmaceutical Fine Chemical Division.
Before establishing his own consultancy, Rathman was in charge of Organic Technical Development at FMC Lithium, advancing from his prior FMC assignments as senior technologist and earlier on, as a bench chemist.
You may also like
Manufacturing
Optima chemical to capitalise on acquisition of lithium product lines
Following its December agreement with Lithium FMC to purchase and license selected lithium products, US custom research and manufacturing company Optima Chemical has launched a range of inorganometallic products under its own brand.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing
As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Ingredients
The impact of Brexit on raw materials testing for the pharmaceutical industry (2026 update)
Since the UK departed from the EU, the pharmaceutical regulatory landscape has undergone significant and lasting change; whereas early uncertainty has largely subsided, the system has evolved into a stable but more complex dual framework
Manufacturing
Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market
Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Ingredients
Pangea Pharmaceuticals launches FDA-approved amlodipine oral solution Sdamlo
Pangea’s Sdamlo, the first FDA-approved amlodipine powder for oral solution, leverages a patent-pending lyophilisation process to enable precise unit-dose delivery and improved administration for paediatric, geriatric and dysphagic patients
Ingredients
Oncodesign Services extends GIP ARRONAX collaboration to secure astatine-211 supply
The company has extended its collaboration with the French radionuclide specialist to secure access to astatine-211, an alpha-emitting radioisotope of growing interest in targeted radiotherapy but constrained by its seven-hour half-life and limited production capacity